chronic constipation

Elobixibat (A 3309) is an inhibitor of the ileal bile acid transporter (IC50: 0.13 nM, 0.53 nM, and 5.8 nM for mouse, human, and canine IBAT). Elobixibat can be used in studies about chronic idiopathic constipation.

Linaclotide acetate is used as an oral guanylate cyclase C agonist linaclotide; 14 amino acid peptide for the potential treatment of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

Prucalopride (R-93877) is a selective, high-affinity 5-HT4A/4B receptor agonist (Ki: 2.5/8 nM). It has >290-fold selectivity for 5-HT4A/4B receptor than other 5-HT receptor subtypes.

Mizagliflozin (GSK-1614235 free base) is a sodium-glucose transporter inhibitor( Ki of 27 nM for human SGLT1). Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic drug that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation.

Lubiprostone (RU-0211), an activator of ClC-2 chloride channels, is used in the therapy of idiopathic chronic constipation.

DS-3801b is a potent, non-macrolide GPR38 agonist and has the potential to be a novel gastrointestinal agonist for the study of functional gastrointestinal disorders (e.g. gastroparesis, chronic constipation).

Elobixibat-d5 is a deuterated compound of Elobixibat. Elobixibat has a CAS number of 439087-18-0. Elobixibat is an inhibitor of the ileal bile acid transporter (IC50: 0.13 nM, 0.53 nM, and 5.8 nM for mouse, human, and canine IBAT). Elobixibat can be used in studies about chronic idiopathic constipation.

Plecanatide acetate is an analogue of Uroguanylin. It is an orally active guanylate cyclase-C (GC-C) receptor agonist.

Velusetrag(TD-5108)is an effective, selective, and highly potent agonist of the 5-HT4 receptor, and being developed for the treatment of gastroparesis, chronic constipation, and irritable bowel syndrome.

Relenopride, a 5-HT agonist, is used potentially for the treatment of chronic constipation.

Elobixibat hydrate, a potent inhibitor of the ileal bile acid transporter (IBAT), exhibits IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human, mouse, and canine IBAT, respectively. It is utilized in the research of chronic idiopathic constipation (CIC).

Linaclotide developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation, and is a potent and selective guanylate cyclase C agonist.